The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs analysts re-evaluate the outlook for the healthcare and banking sectors, two prominent companies have seen adjustments to their price targets. Goldman Sachs adjusted its price target for Regeneron Pharmaceuticals to $965 from $968 while maintaining a Buy rating, following a clinical pipeline assessment. Conversely, Keefe, Bruyette & Woods raised its target for Truist Financial to $55 from $53, driven by a strong second-quarter earnings beat and a revised revenue outlook.
These adjustments occur amid mixed performance among sector peers; market data shows relative stability in regional bank stocks following positive earnings reports from competitors like PNC Financial, which reported net interest income growth in recent filings. For Regeneron, the slight downward adjustment reflects a balance between the growth of its Eylea franchise and increasing competition in the biologics market, consistent with broader sector trends monitoring upcoming regulatory approvals.
Regarding current trading levels, REGN closed at $678.94 (as of July 16, 2026), while TFC stood at $52.5 (as of July 17, 2026). Investors should monitor upcoming US economic catalysts, particularly the Consumer Price Index (CPI) release on July 14, which could influence market sentiment toward large-cap equities and the financial sector.